Topas Therapeutics is advancing a highly differentiated and versatile approach to establish immune tolerance in autoimmune and immune-mediated diseases.
Topas Particle Conjugates, our proprietary, antigen-coupled nanoparticle platform technology, target liver sinusoidal endothelial cells to prompt anti-inflammatory immune responses and drive T cells toward tolerance. The upcoming readout from our Phase 2a clinical trial in celiac disease will validate the power of this new drug modality and its potential to address a broad range of indications, positioning us to deliver significant therapeutic benefits to patients.